Jane Street Group LLC Has $457,000 Stock Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)

Jane Street Group LLC increased its holdings in shares of Bicycle Therapeutics plc (NASDAQ:BCYC) by 35.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,180 shares of the company’s stock after buying an additional 5,310 shares during the period. Jane Street Group LLC’s holdings in Bicycle Therapeutics were worth $457,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BCYC. GAMMA Investing LLC increased its stake in shares of Bicycle Therapeutics by 105.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after acquiring an additional 1,038 shares in the last quarter. L & S Advisors Inc boosted its holdings in shares of Bicycle Therapeutics by 2.4% in the 3rd quarter. L & S Advisors Inc now owns 59,735 shares of the company’s stock worth $1,352,000 after buying an additional 1,400 shares during the last quarter. Assetmark Inc. purchased a new position in Bicycle Therapeutics in the third quarter valued at approximately $34,000. China Universal Asset Management Co. Ltd. raised its stake in Bicycle Therapeutics by 69.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after acquiring an additional 2,918 shares during the period. Finally, Handelsbanken Fonder AB grew its stake in Bicycle Therapeutics by 2.4% in the 3rd quarter. Handelsbanken Fonder AB now owns 218,700 shares of the company’s stock valued at $4,949,000 after buying an additional 5,200 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Analyst Upgrades and Downgrades

BCYC has been the subject of a number of recent research reports. JMP Securities reduced their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a report on Friday, November 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 31st. HC Wainwright dropped their price objective on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a report on Monday, December 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Bicycle Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $35.25.

Insider Activity at Bicycle Therapeutics

In related news, CAO Travis Alvin Thompson sold 6,256 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the completion of the transaction, the chief accounting officer now owns 19,241 shares in the company, valued at approximately $483,141.51. This represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Santiago Arroyo sold 4,943 shares of Bicycle Therapeutics stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $69,646.87. Following the completion of the sale, the insider now owns 69,057 shares in the company, valued at approximately $973,013.13. This represents a 6.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,933 shares of company stock worth $549,501. 8.50% of the stock is owned by company insiders.

Bicycle Therapeutics Price Performance

Bicycle Therapeutics stock opened at $14.88 on Tuesday. The business’s fifty day moving average is $19.27 and its 200 day moving average is $21.86. Bicycle Therapeutics plc has a one year low of $12.17 and a one year high of $28.67. The stock has a market capitalization of $1.03 billion, a PE ratio of -4.52 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. During the same quarter in the prior year, the company earned ($1.26) earnings per share. Bicycle Therapeutics’s revenue was down 50.0% on a year-over-year basis. As a group, sell-side analysts expect that Bicycle Therapeutics plc will post -3.05 EPS for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.